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To assess the clinical efficacy of an NMES device to improve the absolute walking distance 
(AWD) in patients with IC, as an adjunct to the local standard care available at the study sites 
compared to local standard care alone. 
 
Methods: 
An open, multicentre, randomised controlled trial including eight participating centres in 
England. Sites are equally distributed between those that provide SET programmes and those 
that do not. Patients with IC meeting the inclusion and exclusion criteria, and providing 
consent will be randomised, depending on the centre type, to either NMES and locally 
available standard care or standard care alone. The primary endpoint, AWD, will be 
measured at 3 months (the end of the intervention period) by treadmill testing. Secondary 
outcomes include quality of life assessment, compliance with the interventions, economic 
evaluation of the NMES device, and lower limb haemodynamic measures to further the 
understanding of underlying mechanisms. Recruitment is due to commence in February 2018 
and will continue for a total of 15 months. The NESIC trial is funded by the UK Efficacy and 
Mechanism Evaluation (EME) Programme, Medical Research Council (MRC) and National 
Institute for Health Research (NIHR) partnership. ISRCTN 18242823. 
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Intermittent claudication (IC) describes pain in the lower limbs brought on by exertion and 
relieved by rest. It is the commonest manifestation of peripheral arterial disease (PAD) and 
has a significant impact on patients’ exercise tolerance and quality of life (QoL). In the UK, 
approximately 5-10% of adults aged over 55 years are estimated to be suffering with IC (1). 
With an ageing population, the prevalence of IC and its associated health burdens are 
expected to grow (2). 
Under the remit of the UK National Institute for Health Research (NIHR) Efficacy and 
Mechanism Evaluation (EME) programme, the study investigators have designed a 
randomised controlled trial to determine definitive clinical efficacy, mechanistic evaluation 
and cost effectiveness of a novel intervention that has the potential to significantly impact 
care provision and outcomes for patients with IC. In an increasingly stretched healthcare 
system, with barriers to both supervised exercise therapy (SET) provision and attendance, the 
addition of a more accessible, safe and effective non-invasive modality, will provide greater 
flexibility for clinicians and patients in the first-line management of IC and its associated 
health burdens. 
 
Supervised exercise therapy 
UK clinical guidelines published in 2012 by the National Institute for Health and Care 
Excellence (NICE) recommend that all patients diagnosed with IC are offered a programme 
of SET in addition to best medical therapy (BMT), which includes exercise advice (3). The 
American College of Cardiology Foundation/American Heart Association (ACCF/AHA) 
Task Force on Practice Guidelines (4), Trans-Atlantic Inter-Society Consensus Document on 




Cardiology(ESC) guidelines in collaboration with The European Society for Vascular 
Surgery (ESVS) (6)  all support a Level 1 recommendation for supervised exercise therapy in 
the treatment of claudication. 
Studies have shown SET to significantly improve walking distance with a sustained effect 
over time. A Cochrane systematic review of the impact of SET on walking distances was 
carried out in 2006 by Bendermacher et al (7), and was repeated with updated study data in 
2013 by Fokkenrood et al (8). The latter review included randomised controlled trial data 
comparing SET to non-SET management in patients with IC. Fourteen studies were included, 
randomising a total of 1002 participants, followed up for a duration of between 6 weeks and 
12 months. The primary outcome was absolute walking distance (AWD) as measured by 
treadmill testing. There was a significant improvement of AWD with an effect size of 0.69 
(95% Confidence Interval (CI) 0.51-0.86) and 0.48 (95% CI 0.32-0.64) at 3 months and 6 
months, respectively. On average, there was an improvement in AWD of approximately 180 
metres in the SET group (8). 
SET programmes involve at least 30 minutes of physical activity, including various low 
impact exercises, specifically designed to target the lower limbs. Although the duration of 
programmes can vary across UK healthcare trusts, SET is usually carried out within a 
secondary care setting and is supervised by a healthcare practitioner (physiotherapist or nurse 
specialist) once a week for a 3-month period. The SET programme for NESIC will be 
administered as per local guidelines and is not standardised by this protocol, although all are 
based upon NICE Clinical Guideline 147 (3). 
BMT is designed to address cardiovascular risk factors, including smoking cessation, statins 




diabetes, high blood pressure, and other cardiovascular risk factors. It is delivered alongside 
local standard care, verbal exercise advice and/or referral for SET. 
 
Availability of supervised exercise therapy 
Although SET for patients with IC remains the standard of care, access to programmes varies 
significantly amongst secondary care providers across the UK. A postal survey audit 
published by Shalhoub et al in 2009 (9) showed that only 24% of 84 responding UK vascular 
surgeons had access to SET for their IC patients. An online survey audit repeated in 2014 by 
Babber et al (10) was the first audit of SET access following the publication of the 2012 
NICE guidance and was open to vascular surgeons in the UK and Ireland, as well as to 
members of a physiotherapy organisation as the main SET providers. This audit showed only 
35% of 118 respondents had access to SET. 
A study in 2017 by Harwood et al (11) investigated why access to SET may be poor, citing 
funding as the most common barrier to initiating SET programmes in secondary care (33/35; 
94.3%). Other reasons including the lack of appropriate staff, facilities and expertise were 
also cited across 49 NHS Trusts (12). 
Where SET was available, patient compliance was a major concern due to difficulties 
travelling to the SET class, travel expenditure and time away from work preventing 
attendance. Further studies have also cited patient resistance as well as professional self-
interest as preventing the widespread uptake of SET classes across the UK (13). 
In the US there is a well-established evidence base supporting the use of supervised exercise 
in patients with PAD. However, reimbursement via insurance has been limited and SET has 
been underutilised as a result (14). This may change following a 2017 Decision Memo from 




is sufficient for patients with PAD to receive SET through Medicare. Both patient and 
clinician uptake, and longer term success of such programmes is as yet unknown (15). 
In summary, despite clear evidence that SET has significant clinical benefit in patients with 
IC, both clinicians and patients seem unable to fully utilise this non-invasive treatment 
modality as part of first line therapy. 
 
Neuromuscular electrical stimulation as an adjunct to supervised exercise therapy 
Neuromuscular electrical stimulation (NMES) is a non-invasive, low cost treatment strategy 
for patients with IC. The application of NMES has been utilised to enhance peripheral 
circulation. However, as an emerging technology in venous disorders, it has not been properly 
assessed for efficacy in a fully powered clinical trial. 
A pilot study by Varatharajan et al, showed improvements in arterial and venous blood flow 
and time averaged mean velocity during the use of an NMES device, which returned to 
baseline once stimulation stopped (16). A subsequent proof of concept pilot study of 20 
patients with IC showed a significant improvement in AWD (102.3m vs.187.2m, p<0.01), 
and both ‘disease specific’ and ‘generic’ health related QoL measures after using a 
commercially available NMES device for 6 weeks (12). Compliance as assessed by patient 
recorded diaries was 98.5% in the 6-week follow-up period. A systematic review by Williams 
et al included 5 studies utilising various NMES devices as treatment for patients with IC (17). 
Ninety-six patients with IC were compared between control and NMES groups in the 5 
included studies and identified up to 150% improvement in AWD at 4 weeks of intervention 
and 34% at 8 weeks. 
In the NESIC protocol, patients will be supplied with the Revitive IX, a CE marked class IIa 




aspect of the feet whilst the user is seated. The user controls the intensity of the impulses, and 
therapeutic benefit is deemed to occur when impulses are sufficient enough to activate action 
potentials in the calf muscle resulting in ankle flexion. The Revitive IX is designed to be used 
at home with minimal involvement from healthcare professionals. It can be used for up to 3 
hours daily in 30 minute sessions. The retail cost of the device is approximately £160. 
Although some evidence of the efficacy of NMES in the management of patients with IC 
exists, there is a significant paucity of high quality research conducted in a powered and 
controlled manner. The NESIC trial is vital to robustly identify the contribution of such 
devices compared to the current gold standard recommended practice of SET and the 
available standard of care offered in the majority of the UK and Ireland, which is BMT 
(including exercise advice). 
 
Methodology 
The coordinating centre received research ethics committee approval (reference 17/LO/1918) 
and a letter of no objection from the UK Competent Authority. NESIC is registered on a 
public trials registry, ISRCTN: 18242823. 
Figure 1 shows a consort diagram of the patient pathway through the study, and Table 1 
details the inclusion and exclusion criteria. The study population comprises adults presenting 
to vascular outpatient clinics diagnosed with IC in one or both legs who meet all the inclusion 
exclusion criteria. NESIC is a two arm randomised controlled trial, where the control is best 
locally available therapy, which includes BMT AND either exercise advice or SET, 






Centres where supervised exercise therapy is available 
Following consent and administration of baseline assessments, patients will be randomised to 
BMT, SET and NMES, or BMT and SET only. Patients will be referred for SET classes as 
per local standard care. Compliance will be recorded via medical records as well as patient 
recorded diaries. Patients randomised to receive the NMES device will be trained how to use 
the equipment at home and advised to complete at least one pre-programmed 30 minute 
session of NMES per day. In line with the instructions for use, the device should be used for a 
minimum of 30 minutes per day up to a maximum of 3 hours per day. Patients will record 
compliance in a self-completed diary which will be cross referenced with a voltage/current 
data logger attached to a proportion of NMES devices. 
 
Centres where supervised exercise therapy is not available 
Centres that do not provide SET will randomise patients to BMT (including exercise advice) 
and NMES, or BMT (including exercise advice) alone. Baseline assessments will be recorded 
in the same way as SET centres, and compliance to locally available BMT will be measured 
via drug compliance and smoking cessation at follow up visits. 
The treatment phase of the study will be three months in duration and text message services 
will remind patients to either attend their SET classes and/or record in their diaries any 
unsupervised exercise they have performed, as well as to use and record usage of their NMES 
device (if in an NMES study arm). 
Follow up for both centre types will be performed in the same way. The first follow up at 3 
months, the end of the treatment period, will assess AWD using treadmill testing. 
Haemodynamic assessments will be performed via laser Doppler flowmetry and duplex 




performed as per the baseline assessment, and safety information will be recorded and 
reported to the UK Competent Authority in line with requirements. 
The treadmill test, clinical examination, medication review, QoL questionnaires, laser 
Doppler flowmetry and safety reporting will occur at 6 months and again at 12 months follow 
up. Full details of the study assessments can be found in the study protocol, written in 
accordance with SPIRIT guidelines (18). The 12-month assessment marks the end of study 
participation, at which point patients will revert to standard care. 
 
Primary outcome 
The primary endpoint of the study is AWD at 3 months as determined by a standardised 
treadmill test using the Gardner Skinner graded protocol (19). In this protocol, the treadmill 
starts at 3.2 km/h at a 0% incline, and the gradient of the treadmill is increased by 2% every 2 
minutes. Patients indicate the start of their claudication pain, recorded as the initial 
claudication distance, and the test stops at the point the patient does not want to continue due 
to lower limb pain; this is the AWD. The patient will not be given a final score to prevent 
bias. 
 
The 3-month intervention period is in line with NICE guidelines for SET. Four previous 
studies have reported on improvement in AWD for the same population of patients (20-23) 
with three of the studies reporting AWD at 3 months. These reported an improvement in 
AWD of between 75-90m (21-23). The improvement detected at 6 months varied from 41m 
(20) to 170m (21) across all studies. The MIMIC trial reported an improvement in AWD at 
24 months but did not report the effect size at 3 months. None of the studies clearly reported 








Secondary outcomes, including resource use, adverse events, validated health related 
QoL questionnaires (EQ-5D-5L and SF36), and compliance data, will assist in modelling 
for economic evaluation of the intervention compared to standard treatment practice in 
order to assess cost effectiveness. 
In addition to an assessment of clinical efficacy of NMES, haemodynamic measurements 
at the common femoral artery, including time averaged mean volume (TAMV, cm/s) and 
blood flow (cc/min) will be carried out by duplex ultrasound. In addition, skin 
microcirculation (blood flux) will be measured by laser Doppler flowmetry. These 
parameters will help further the understanding of underlying mechanisms for any changes 
in clinical and subjective outcomes. 
 
Sample size 
From pilot work and clinical judgement, using NMES together with best locally available 
therapy should result in an improvement in mean AWD of at least 60m after 3 months in the 
intervention group. This improvement is deemed as clinically important. Therefore, we have 
adopted the same assumptions of effect size and standard deviation for the sample size 
calculation. These parameters are deemed as providing significant clinical benefit in the IC 





The study has 90% power with a two sided alpha = 0.05 to detect a difference of 60m in the 
mean AWD at 3 months between the intervention and the control groups. 
Assuming a 10% dropout rate, the sample size required for this study is 192 participants. The 
sample size was computed for a two sample means test using Stata (version13, StataCorp). 
 
Study management and monitoring 
In line with NIHR recommendations, a Trial Steering Committee (TSC) and independent 
Data Monitoring Committee (iDMC) have been appointed. An iDMC meeting will be held 
prior to first patient first visit, following completion of an internal pilot study, and will then 
be held one month prior to each TSC meeting. Full details of the iDMC’s remit (including the 
stopping rules for effectiveness and futility) will be agreed in accordance with the charter at 
the first meeting, before any unblinded data are available or seen. 




All randomised patients will be followed up to 12 months unless they specifically ask to be 
withdrawn, as per the intention to treat principle. In line with this type of analysis, patients 
lost to follow up or withdrawn from the study will not be replaced. 
The primary analysis will estimate the difference between the groups in change from baseline 
AWD using an ANCOVA model with baseline AWD as a covariate. Repeated measure 
analysis, adjusted for stratification by centre, will investigate the relationship between AWD 




treatment effects that account for compliance with the allocated intervention (NMES, SET, 
BMT). Where necessary, data will be transformed to meet normality assumptions. The 
primary economic analysis will calculate costs and quality-adjusted life years (QALYs) over 
the duration of the trial and measured from EQ-5D-5L data collected in the trial. The decision 
model will use information from the trial and other sources to project costs and QALYs over 
the lifetime of the patients, by estimating the effect of IC on mortality, QoL and resource use, 
and the impact of the intervention on these endpoints. 
All statistical tests will be two tailed with a 5% significance level. To recruit sufficient 
subjects, eight centres will participate in the study; four centres with exercise advice only as 
locally available therapy, and four providing SET. 
 
Recruitment 
Once eligibility has been confirmed, subjects will be randomised to one of the two arms of 
the study and assigned a pseudonymised study number unique to each individual enrolled on 
the trial. Randomisation will be blocked with random block sizes and stratified by centre 
type. 
Through feasibility data collected from each centre, a conservative estimate of 15 months is 
required to reach the target recruitment of 192 patients for this study, with each site aiming to 
recruit 24 patients in total. 
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